Examples of randomized trials show both an extension of the average survival time of patients after using OCT and a decrease in AFP concentration [301,305], as well as a lack of impact of this SSA on life extension, tumor regression or changes in AFP concentration in advanced HCC [300]. This evidence concerns the gene AFP and hepatocellular carcinoma.